Phase II trial of pathology-based tripartite treatment stratification for patients with CNS germ cell tumors: A long-term follow-up study
Initial treatment intensity is crucial for managing non-germinomatous GCTs, while long-term follow-up for relapse and complications is imperative in germinomas. Irradiation extending beyond the immediate tumor site is essential for basal ganglia germinomas. Addressing relapse in non-germinomatous GCT remains a significant challenge.
Authors
- Eiichi Ishikawa (ORCID: https://orcid.org/0000-0001-9224-9767)
- Shinji Kawabata (ORCID: https://orcid.org/0000-0001-5007-5279)
- Shinji Yamashita (ORCID: https://orcid.org/0000-0001-5859-2828)
- Kazuhiko Takabatake (ORCID: https://orcid.org/0000-0003-4978-3926)
- Shota Tanaka (ORCID: https://orcid.org/0009-0003-4128-2825)
- Ryo Nishikawa (ORCID: https://orcid.org/0000-0001-5617-8068)
- Daisuke Kuga (ORCID: https://orcid.org/0000-0002-9493-0748)
- Akitake Mukasa (ORCID: https://orcid.org/0000-0001-7776-9086)
- Michinari Okamoto (ORCID: https://orcid.org/0000-0002-6762-178X)
- Takeshi Takayasu
- Naoki Shinojima (ORCID: https://orcid.org/0000-0003-3352-7936)
- Manabu Natsumeda (ORCID: https://orcid.org/0000-0003-3098-8323)
- Kentaro Fujii (ORCID: https://orcid.org/0000-0002-3692-493X)
- Mitsutoshi Nakada (ORCID: https://orcid.org/0000-0001-9419-6101)
- Ai Muroi (ORCID: https://orcid.org/0000-0002-4983-6306)
- Takamitsu Fujimaki (ORCID: https://orcid.org/0000-0002-9643-5548)
- Masahiro Shin (ORCID: https://orcid.org/0000-0001-8025-127X)
- Yoshiki Arakawa (ORCID: https://orcid.org/0000-0003-4626-4645)
- Masayuki Kanamori (ORCID: https://orcid.org/0000-0002-3380-1192)
- Shigeru Yamaguchi (ORCID: https://orcid.org/0000-0003-2304-8448)
- Yutaka Fujioka (ORCID: https://orcid.org/0000-0002-8506-9343)
- Yukihiko Sonoda (ORCID: https://orcid.org/0000-0001-7651-1374)
- Yohei Mineharu (ORCID: https://orcid.org/0000-0002-6346-3999)
- Tomonari Suzuki (ORCID: https://orcid.org/0000-0002-8985-6862)
- Fumi Higuchi
- Akio Asai (ORCID: https://orcid.org/0000-0001-7348-4403)
- Masahiko Wanibuchi (ORCID: https://orcid.org/0000-0002-1856-7123)
- Fumiyuki Yamasaki (ORCID: https://orcid.org/0000-0003-0164-6295)
- Joji Ishida (ORCID: https://orcid.org/0000-0003-1233-2793)
- Hirokazu Takami (ORCID: https://orcid.org/0000-0001-9742-7462)
- Hideo Takeshima (ORCID: https://orcid.org/0000-0002-5699-7642)
- Masamichi Takahashi (ORCID: https://orcid.org/0000-0001-8792-1993)
- Isao Date
- Keisuke Miyake (ORCID: https://orcid.org/0000-0002-7611-6486)
- Yoshitaka Narita (ORCID: https://orcid.org/0000-0003-4303-6006)
- Toshiya Ichinose (ORCID: https://orcid.org/0000-0003-0104-7313)
- Kenichiro Matsuda
- Masao Matsutani
- Nobuhito Saito
- N. Kagawa
Institutions
- Kanazawa University (JP)
- Yamagata University (JP)
- Hiroshima University (JP)
- University of Miyazaki (JP)
- Kansai Medical University (JP)
- Kyushu University (JP)
- University of Tsukuba (JP)
- Okayama University (JP)
- Kanazawa Medical University (JP)
- Yamaguchi University (JP)
- Tohoku University (JP)
- Kagawa University (JP)
- Hokkaido University (JP)
- Kyoto University (JP)
- Osaka City University (JP)
- National Cancer Center (US)
- University of Tokyo Hospital (JP)
- Saitama Medical University Hospital (JP)
- Saitama International Medical Center (JP)
- Neurological Surgery (US)
- Niigata University (JP)
- Saitama Medical University (JP)
- Teikyo University (JP)
- Osaka University of Pharmaceutical Sciences (JP)
- Kumamoto University (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2024-10-31
- DOI
- https://doi.org/10.1093/neuonc/noae229
- Citations
- 3
- Primary Topic
- Testicular diseases and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.72
Funders
- Japan Society for the Promotion of Science